{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:40:48Z","timestamp":1786653648918,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze the medical management of primary open-angle glaucoma (POAG) and ocular hypertension (OHT) and the placement of fixed-drug combination drugs (FDC) in the treatment paradigm at a tertiary eye care center in South India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective study (January 2011\u2013December 2015) of newly diagnosed POAG and OHT patients (\u226518 years) with \u22655 years follow-up. Primary outcome included percentage use of different antiglaucoma drugs (at initiation) and FDCs at the first, second, and third progression (sequencing). Secondary outcomes: Percentage discontinuation for different FDCs, efficacy parameters (decrease in intraocular pressure (IOP)\/visual field), adverse events, and the median number of antiglaucoma medications (AGMs) after 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three hundred and seventy eyes (198 patients) were analyzed; 84% of them had POAG. Prostaglandin analogs (PGAs) were the most common (66.2%). FDCs were started in 48 eyes (12.9%), with brimonidine + timolol combination being the most common. FDC usage at subsequent modifications was 10.1%, 24.04%, and 30.0%. Beta-blockers and PGAs were the most frequently prescribed AGMs in our practice pattern, with \u03b2-blockers being the most consistent one.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study is a fairly large study with a minimum of a 5-year follow-up of patients with POAG and OHT and gives insights into the treatment patterns, use of FDCs, and the need for multiple medications over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_694_23","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:01:24Z","timestamp":1713243684000},"page":"896-901","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Understanding the treatment paradigm and the sequencing of antiglaucoma fixed-dose combinations in a tertiary center in South India"],"prefix":"10.4103","volume":"72","author":[{"given":"Ronnie","family":"George","sequence":"first","affiliation":[{"name":"Smt. Jadhavbai Nathmal Singhvee Glaucoma Services, Sankara Nerthralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praggya","family":"Mishra","sequence":"additional","affiliation":[{"name":"Smt. Jadhavbai Nathmal Singhvee Glaucoma Services, Sankara Nerthralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balekudaru","family":"Shantha","sequence":"additional","affiliation":[{"name":"Smt. Jadhavbai Nathmal Singhvee Glaucoma Services, Sankara Nerthralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingam","family":"Vijaya","sequence":"additional","affiliation":[{"name":"Smt. Jadhavbai Nathmal Singhvee Glaucoma Services, Sankara Nerthralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Maksane","sequence":"additional","affiliation":[{"name":"Medical Affairs, Novartis Healthcare Private Limited, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Gurha","sequence":"additional","affiliation":[{"name":"Medical Affairs, Novartis Healthcare Private Limited, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/ICU.0b013e3280895aea","article-title":"Glaucoma as a neurodegenerative disease","volume":"18","author":"Gupta","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for Glaucoma progression and effect of treatment: The early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R4-20260504","first-page":"276","article-title":"Delaying treatment of OHT. The OHTS","volume":"128","author":"Kass","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/IJG.0000000000000081","article-title":"The relation between sociodemographic factors and persistence with topical glaucoma medication","volume":"24","author":"Leung","year":"2015","journal-title":"J Glaucoma"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The most common barriers to glaucoma medication adherence: A cross-sectional survey","volume":"122","author":"Newman-Casey","year":"2015","journal-title":"Ophthalmology"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","article-title":"Adherence to fixed-combination versus unfixed travoprost 0.004%\/timolol 0.5% for glaucoma\/OHT. A randomized trial","volume":"176","author":"Barnebey","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","article-title":"Glaucoma treatment trends: A review","volume":"5","author":"Conlon","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/eye.2014.114","article-title":"Glaucoma prescribing trends in England 2000 to 2012","volume":"28","author":"Connor","year":"2014","journal-title":"Eye"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/0301-4738.40362","article-title":"Practical approach to medical management of glaucoma","volume":"56","author":"Paarikh","year":"2008","journal-title":"Indian J Ophthalmol"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00061198-200210000-00001","article-title":"Translating OHTS results into clinical practice","volume":"11","author":"Cioffi","year":"2002","journal-title":"J Glaucoma"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0301-4738.44495","article-title":"Patient-reported barriers to glaucoma medication access, use, and adherence in Southern India","volume":"57","author":"Sleath","year":"2009","journal-title":"Indian J Ophthalmol"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ogla.2020.09.002","article-title":"Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: An administrative database analysis","volume":"4","author":"Schwartz","year":"2021","journal-title":"Ophthalmol Glaucoma"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"223.","DOI":"10.1186\/s12886-020-01508-8","article-title":"Persistence and treatment patterns of fixed combination drugs for glaucoma: A retrospective claims database study in Japan","volume":"20","author":"Kashiwagi","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5455\/njppp.2017.7.0822624082016","article-title":"Prescribing pattern and adverse events of drugs used in patients with primary open-angle glaucoma (POAG) attending a tertiary care hospital: Retrospective study","volume":"7","author":"Rai","year":"2017","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"6509809.","DOI":"10.1155\/2016\/6509809","article-title":"Medical management of glaucoma in the 21st century from a Canadian perspective","volume":"2016","author":"Harasymowycz","year":"2016","journal-title":"J Ophthalmol"},{"key":"R17-20260504","first-page":"1580","article-title":"Understanding practice patterns of glaucoma sub-specialists in India","volume":"10","author":"Chaudhari","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/cer.15.57","article-title":"Practice patterns and treatment changes for open-angle glaucoma: The RiGOR study","volume":"5","author":"Coleman","year":"2016","journal-title":"J Comp Eff Res"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0253-7613.108279","article-title":"Drug use in primary open-angle glaucoma. A prospective study at a tertiary care teaching hospital","volume":"45","author":"Yadav","year":"2013","journal-title":"Indian J Pharmacol"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2165\/00002512-200724120-00004","article-title":"Use of fixed-dose combination drugs for the treatment of glaucoma","volume":"24","author":"Khouri","year":"2007","journal-title":"Drugs Aging"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/bjophthalmol-2016-308505","article-title":"Treatment patterns and medication adherence of patients with glaucoma in South Korea","volume":"101","author":"Kim","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","article-title":"Persistence of topical glaucoma medication: A nationwide population-based cohort study in Taiwan","volume":"132","author":"Hwang","year":"2014","journal-title":"JAMA ophthalmol"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1185\/03007990903260129","article-title":"Glaucoma medication persistence with a fixed combination versus multiple bottles","volume":"25","author":"Higginbotham","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0161-6420(03)00076-9","article-title":"Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years","volume":"110","author":"Eid","year":"2003","journal-title":"Ophthalmology"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","article-title":"Compliance barriers in glaucoma: A systematic classification","volume":"12","author":"Tsai","year":"2003","journal-title":"J Glaucoma"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0301-4738.44495","article-title":"Patient-reported barriers to glaucoma medication access, use, and adherence in Southern India","volume":"57","author":"Sleath","year":"2009","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_694_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:27Z","timestamp":1786650027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_694_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_694_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"2023-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}